Difference between revisions of "IVAX Corporation"

From Powerbase
Jump to: navigation, search
(new page stub)
 
Line 5: Line 5:
  
 
ChemSource is reported to have 'recently entered into a license agreement with [[Novartis]] Pharma AG to utilize the patented multi-dose dry powder inhaler, Airmax, for Novartis's trademarked medicines Foradil and Miflonide in the European Union and certain other countries'<ref> <i>Plunkett's Health Care Industry Almanac</i>. 'IVAX Corporation.' January 2004</ref>.
 
ChemSource is reported to have 'recently entered into a license agreement with [[Novartis]] Pharma AG to utilize the patented multi-dose dry powder inhaler, Airmax, for Novartis's trademarked medicines Foradil and Miflonide in the European Union and certain other countries'<ref> <i>Plunkett's Health Care Industry Almanac</i>. 'IVAX Corporation.' January 2004</ref>.
 +
 +
In July 2003, <i>Business Wire</i> reports that IVAX 'received the first of a series of payments from [[B Braun Melsungen]] AG, under a number of agreements, for certain patent and product rights and for settlement of litigation'<ref><i>Business Wire</i> 'IVAX Reports Increased Revenues and Net Income for 2nd Quarter of 2003; 2Q2003 Net Revenues Up 22% to $343 Million, Net Income Up 30% to $41.3 Million' 30th July 2003. Miami</ref>.
  
 
==Brands, Divisions and Affiliates==
 
==Brands, Divisions and Affiliates==

Revision as of 18:23, 22 May 2008

IVAX Corporation

Aquisitions

In 2004, IVAX is reported to have aquired ChemSource Corporation (which is based in Puerto Rico)[1] .

ChemSource is reported to have 'recently entered into a license agreement with Novartis Pharma AG to utilize the patented multi-dose dry powder inhaler, Airmax, for Novartis's trademarked medicines Foradil and Miflonide in the European Union and certain other countries'[2].

In July 2003, Business Wire reports that IVAX 'received the first of a series of payments from B Braun Melsungen AG, under a number of agreements, for certain patent and product rights and for settlement of litigation'[3].

Brands, Divisions and Affiliates

In 2004, Plunkett's Health Care Industry Almanac reports the following 'Brands/Divisions/Affiliates' of IVAX[4]...

References

  1. Plunkett's Health Care Industry Almanac. 'IVAX Corporation.' January 2004
  2. Plunkett's Health Care Industry Almanac. 'IVAX Corporation.' January 2004
  3. Business Wire 'IVAX Reports Increased Revenues and Net Income for 2nd Quarter of 2003; 2Q2003 Net Revenues Up 22% to $343 Million, Net Income Up 30% to $41.3 Million' 30th July 2003. Miami
  4. Plunkett's Health Care Industry Almanac. 'IVAX Corporation.' January 2004